Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› Kayseri
Clinical trial register · Turkey

Clinical Trials in Kayseri, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Turkey and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 5418 matching records held by the registry are in this view. Synced 11 Oct 2026, 03:18 UTC
5418
Studies in scope
all four open statuses
2461
Recruiting now
open to new participants
548
Lead sponsors
across recruiting studies
Top sites
Ankara 101 Istanbul 81 Izmir 54 Adana 36 Antalya 31
Narrow the registerReset
Recruitment status
Phase
Site location
Ankara101 Istanbul81 Izmir54 Adana36 Antalya31
All 57 locations
Target enrolment
to

Trials with a site in Kayseri

19 of 5418 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Turkey
Start
Recruiting
AstraZeneca
Phase 3
2,800
Adapazarı, Ankara, Antalya, Dinar, İzmit, Kahramanmaraş, Kayseri, Kazımkarabekir
2026-09-01
Recruiting
AstraZeneca
Phase 3
800
Adana, Ankara, Bursa, Izmir, Kayseri, Samsun
2026-07-06
Recruiting
AstraZeneca
Phase 3
900
Adana, Ankara, Antalya, Bakırköy, Gaziantep, Kayseri, Yüreğir
2026-07-06
Recruiting
AstraZeneca
Observational
2,150
Ankara, Adana, Gaziantep, Istanbul, Kayseri
2026-05-06
Active, closed
AstraZeneca
Phase 2
222
Adana, Adapazarı, Kahramanmaraş, Kayseri, Kocaeli
2025-12-05
Recruiting
AstraZeneca
Phase 2
987
Adana, Ankara, Bursa, İzmit, Kayseri, Mersin
2025-06-27
Recruiting
AstraZeneca
Phase 3
15,100
Afyonkarahisar, Ankara, Antalya, Çanakkale, Edirne, Istanbul, Izmir, Kayseri
2025-06-04
Recruiting
AstraZeneca
Phase 2
540
Adana, Ankara, Bursa, Gaziantep, Istanbul, Kayseri, Mersin
2025-03-26
Recruiting
AstraZeneca
Phase 3
990
Adana, Ankara, Istanbul, Kayseri, Kocaeli, Mersin
2025-03-25
Recruiting
AstraZeneca
Phase 3
5,000
Adana, Adapazarı, Altındağ, Ankara, Antalya, Haliliye, Kahramanmaraş, Kayseri
2025-03-03
Active, closed
AstraZeneca
Phase 3
339
Cordaleo, Istanbul, Kayseri, Samsun
2024-06-29
Recruiting
AstraZeneca
Phase 3
100
Ankara, Istanbul, Kayseri, Umraniye
2024-03-14
Active, closed
AstraZeneca
Phase 3
1,902
Adapazarı, Ankara, Istanbul, Kayseri, Samsun
2023-11-14
Active, closed
AstraZeneca
Phase 3
1,835
Adapazarı, Ankara, Bursa, Dinar, Kahramanmaraş, Kayseri, Kocaeli
2023-11-07
Active, closed
AstraZeneca
Phase 3
363
Adapazarı, Ankara, Istanbul, Izmir, Kahramanmaraş, Kayseri, Kocaeli
2022-02-15
Active, closed
AstraZeneca
Phase 3
315
Adana, Ankara, Cordaleo, Izmir, Kadıkoy/Istanbul, Kayseri
2021-06-30
Active, closed
AstraZeneca
Phase 3
1,012
Ankara, Antalya, Eskişehir, Istanbul, Izmir, Kayseri
2020-07-13
Rows per page Showing 1–19 of 19
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Turkish investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 11 October 2026. https://priyalifescience.com/clinical-trials-turkey/city/kayseri

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Turkey and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 5,418 studies in total at the last sync on 11 Oct 2026, 03:18 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 19 of those studies with a site in Kayseri that also match the filters currently applied.

How many clinical trials are recruiting in Kayseri?

11 of the 19 studies on this page are recruiting new participants as of the 11 Oct 2026, 03:18 UTC sync. A further 0 have not yet opened recruitment, 8 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Kayseri), 19 studies
PhaseStudiesRecruitingShare
Phase 315878.9%
Phase 23215.8%
Observational115.3%

Most active sponsors

Lead sponsors with the most studies (Kayseri)
Lead sponsorStudiesRecruiting
AstraZeneca1911
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.